ArticleAnnals of surgical oncology2026
SIGLEC12 Predicts Prognosis and Chemotherapeutic Vulnerability in Patients with Pancreatic Cancer.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundEmerging evidence implicates sialic acid-binding immunoglobulin-like lectin (SIGLEC) family members as emerging immune checkpoints and as having a role in cancer progression. However, as a relatively unique SIGLEC member, SIGLEC12 has rarely been studied in cancer, and its clinical significance in pancreatic ductal adenocarcinoma (PDAC) remains largely unknown. This study aimed to investigate the expression pattern and prognostic value of SIGLEC12 in PDAC.
methodsA retrospective cohort of 145 patients with PDAC was enrolled. SIGLEC12 expression was assessed by immunohistochemistry on tumor microarrays. The association between SIGLEC12 and overall survival (OS) and recurrence-free survival (RFS) was evaluated using the Kaplan-Meier method and Cox regression analysis. The potential effect modification of SIGLEC12 was assessed by interaction analyses.
resultsSIGLEC12 expression was significantly upregulated in PDAC tissues at both protein and messenger RNA levels (P < 0.001). High SIGLEC12 expression was associated with poorer OS and RFS and was an independent prognostic factor (OS: hazard ratio [HR] 1.928, P = 0.0004; RFS: HR 1.569, P = 0.022). Interaction analyses revealed that the prognostic effects of carbohydrate antigen 19-9 (CA19‑9) and adjuvant chemotherapy (ACT) were significantly modified by SIGLEC12. Notably, elevated CA19-9 predicted poorer survival, and ACT improved survival only in patients with low SIGLEC12 expression and not in those with high SIGLEC12 expression.
conclusionsSIGLEC12 is frequently upregulated in PDAC and predicts poor prognosis. Notably, our exploratory findings suggest that SIGLEC12 may modify the prognostic effect of CA19‑9 and the therapeutic benefit of ACT. These findings position SIGLEC12 as a promising prognostic biomarker and novel therapeutic target in PDAC, with potential for further roles in refining risk stratification and guiding personalized treatment decisions.
Indexed as
Identifiers
42365150What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.